EMR B: Cost effectiveness results for Tuberculosis
This Table provides summary results of the total populationlevel costs, effects and costeffectiveness for the selected WHO subregion and risk factor / disease for the year 2000.
KEY
I$  International Dollars
Program Costs include costs of administration, media, training etc
Patient Costs include costs of hospital visits, drugs, etc
Incremental costeffectiveness ratio (ICER) is defined as the incremental change in cost, divided by the incremental change in effectiveness. ICERs are reported for the successive set of interventions that would be selected at expanding levels of resource availability, starting with the intervention with the lowest cost per DALY averted, then moving to the next most costeffective combination intervention out of the remaining available set of interventions.
Dominated is used to denote an intervention that is more costly and/or less effective than other, more efficient (single or combined) interventions; i.e. dominated interventions do not appear on the expansion path of most costeffective strategies.

Summary
Summary of the methodologies used in the analysis 
Published research report
pdf, 122kb 
Excel Spreadsheet
xls, 16kb
Download this table in excel
Interventions:Codes_and_Descriptions  Coverage  Cost per year (I$, millions) per one million_population [i.e. cost per capita]  % Program costs  % Patient costs  DALYs averted per year per one million_population  Average Cost per DALY averted  Incremental Cost per DALY averted 
TB1: SmearPos: Treatment of new smearpositive cases only under DOTS  50%  0.70  84%  16%  62,543  11  Dominated 
TB2: SmearPosNeg: As for SmearPos, plus treatment of smearnegative cases under DOTS  50%  0.76  81%  19%  65,058  12  Dominated 
TB3: SmearPosMDR: As for SmearPos, plus DOTSplus treatment  50%  0.93  68%  32%  63,871  14  Dominated 
TB4: Combination: As SmearPos, plus DOTS treatment of smearnegative cases plus DOTSplus standardized secondline drug retreatment  50%  0.98  67%  33%  66,361  15  Dominated 
TB5: SmearPos: Treatment of new smearpositive cases only under DOTS  80%  1.11  84%  16%  100,069  11  11 
TB6: SmearPosNeg: As for SmearPos, plus treatment of smearnegative cases under DOTS  80%  1.20  81%  19%  104,093  12  Dominated 
TB7: SmearPosMDR: As for SmearPos, plus DOTSplus treatment  80%  1.45  68%  32%  102,193  14  Dominated 
TB8: Combination: As SmearPos, plus DOTS treatment of smearnegative cases plus DOTSplus standardized secondline drug retreatment  80%  1.55  66%  34%  106,178  15  Dominated 
TB9: SmearPos: Treatment of new smearpositive cases only under DOTS  95%  1.41  85%  15%  118,831  12  16 
TB10: SmearPosNeg: As for SmearPos, plus treatment of smearnegative cases under DOTS  95%  1.55  82%  18%  123,611  13  30 
TB11: SmearPosMDR: As for SmearPos, plus DOTSplus treatment  95%  1.85  70%  30%  121,355  15  Dominated 
TB12: Combination: As SmearPos, plus DOTS treatment of smearnegative cases plus DOTSplus standardized secondline drug retreatment  95%  1.98  69%  31%  126,086  16  174 